Overview

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study is designed to estimate the effect of fluconazole (200 mg BID for 2 days), a moderate CYP3A4 inhibitor on the pharmacokinetics of a single 8 mg oral dose of fesoterodine in healthy adult subjects.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Pfizer
Treatments:
Fesoterodine
Fluconazole
Criteria
Inclusion Criteria:

- Healthy subjects between the ages of 18 and 55 years

Exclusion Criteria:

- Not healthy subjects. subjects with acute or chronic medical or psychiatric condition
or laboratory abnormality